Efficacy and Safety of Antioxidant Treatment With {alpha}-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 Trial Full Text
Diabetes Care,

Ziegler D et al. – Four–year treatment with α–lipoic acid (ALA) in mild–to–moderate diabetic distal symmetric sensorimotor polyneuropathy (DSPN) did not influence the primary composite end point but resulted in a clinically meaningful improvement and prevention of progression of neuropathic impairments and was well tolerated. Because the primary composite end point did not deteriorate significantly in placebo subjects, secondary prevention of its progression by ALA according to the trial design was not feasible.

Methods
  • In a multicenter randomized double–blind parallel–group trial, 460 diabetic patients with mild–to–moderate DSPN were randomly assigned to oral treatment with 600 mg ALA four times daily (n = 233) or placebo (n = 227) for 4 years.
  • Primary end point was a composite score (Neuropathy Impairment Score [NIS]–Lower Limbs [NIS–LL] and seven neurophysiologic tests).
  • Secondary outcome measures included NIS, NIS–LL, nerve conduction, and quantitative sensory tests (QSTs).

Results
  • Change in primary end point from baseline to 4 years showed no significant difference between treatment groups (P = 0.105).
  • Change from baseline was significantly better with ALA than placebo for NIS (P = 0.028), NIS–LL (P = 0.05), and NIS–LL muscular weakness subscore (P = 0.045).
  • More patients showed a clinically meaningful improvement and fewer showed progression of NIS (P = 0.013) and NIS–LL (P = 0.025) with ALA than with placebo.
  • Nerve conduction and QST results did not significantly worsen with placebo.
  • Global assessment of treatment tolerability and discontinuations due to lack of tolerability did not differ between the groups.
  • The rates of serious adverse events were higher on ALA (38.1%) than on placebo (28.0%).

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Association between sugar-sweetened beverages and type 2 diabetes: a meta-analysis Journal of Diabetes Investigation, November 13, 2014    Evidence Based Medicine    Review Article

2 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

3 Chemical in coffee may help prevent obesity-related disease University of Georgia Research News, November 18, 2014

4 Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial Diabetes Care, September 26, 2014    Clinical Article

5 The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus Canadian Journal of Diabetes, October 28, 2014    Review Article

6 Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States Advances in Therapy, November 21, 2014    Clinical Article

7 Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care, November 4, 2014    Clinical Article

8 Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care, October 24, 2014    Clinical Article

9 Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy Endocrine Practice, November 7, 2014    Clinical Article

10 Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial Diabetic Medicine, November 12, 2014    Clinical Article

11 A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise Diabetes/Metabolism Research and Reviews, November 6, 2014    Clinical Article

12 Optimal glucocorticoid replacement in adrenal insufficiency Best Practice & Research Clinical Endocrinology & Metabolism, November 12, 2014    Review Article

13 The effect of nopal (Opuntia Ficus Indica) on postprandial blood glucose, incretins, and antioxidant activity in Mexican patients with type 2 diabetes after consumption of two different composition breakfasts Journal of the Academy of Nutrition and Dietetics, November 11, 2014    Clinical Article

14 Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies Full Text BMC Cardiovascular Disorders, November 17, 2014    Free full text    Evidence Based Medicine    Review Article    Clinical Article

15 Effects of low dose metformin in adolescents with type I diabetes mellitus: A randomized, double-blinded placebo-controlled study Full Text Pediatric Diabetes, April 7, 2014    Free full text    Clinical Article

16 Thyroid incidentalomas on PET imaging - Evaluation of management and clinical outcomes The Surgeon, August 11, 2014    Clinical Article

17 Prognostic factors for disease-specific survival in 108 patients with Hurthle cell thyroid carcinoma: A single-institution experience Full Text BMC Cancer, November 11, 2014    Free full text    Clinical Article

18 High protein weight loss diets in obese subjects with type 2 diabetes mellitus Nutrition, Metabolism & Cardiovascular Diseases, January 3, 2014    Clinical Article

19 Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials Full Text Drug Design, Development and Therapy, November 12, 2014    Free full text    Evidence Based Medicine    Review Article

20 Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide? Diabetic Medicine, November 14, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore